ChemoCentryx ContactSite Map
News & Events

Overview

Corporate Governance

Annual Reports

SEC Filings


Stock Information

Press Releases

Events & Presentations

contact Info

FAQs

Shareholder Tools

ChemoCentryx is a biopharmaceutical company focused exclusively on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. Our drug candidates target specific chemokines or chemo-attractant receptors, thereby blocking the inflammatory response driven by that particular chemokine while leaving the rest of the immune system unaffected. Our goal is to discover, develop and commercialize therapeutics with distinct advantages over currently marketed therapies in our disease areas of focus, thereby maximizing shareholder value.

Stock Chart
Stock price graph
     
Stock Quote
NASDAQ: CCXI
Price:
5.38
Change:
+ 0.04
Day High:
5.41
Day Low:
5.30
Volume:
5,800
10:46 AM ET on Oct 21, 2014
Delayed at least 20 minutes.
Provided by eSignal.

View all »   RSSRecent News

Oct 21, 2014
ChemoCentryx's Orally Administered CCR9 Inhibitor, CCX507, Shown to be Well Tolerated and Effective in CCR9 Blockade in Phase I Study

Oct 20, 2014
ChemoCentryx Releases Phase III SHIELD 4 Clinical Results in Patients With Crohn's Disease

Sep 22, 2014
ChemoCentryx Appoints Israel F. Charo, M.D., Ph.D., Senior Vice President of Research

^ Return to Top